# a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

> **NCT04776330** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Myeloma
- Neoplasm, Plasma Cell
- Multiple Myeloma in Relapse

## Interventions

- **BIOLOGICAL:** BCMA targeted prime CAR-T cells

## Key facts

- **NCT ID:** NCT04776330
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776330, "a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04776330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*